- Development collaboration integrates Sartorius Stedim Biotech’s BIOSTAT® STR bioreactors and Repligen’s
XCell™ ATF cell retention control technology
- Customers to benefit from simplified, scalable solutions for intensified cell culture
GÖTTINGEN, Germany and WALTHAM, Mass., Sept. 04, 2018 (GLOBE NEWSWIRE) -- Sartorius Stedim Biotech (SSB)
(Euronext: DIM), a leading international supplier for the biopharmaceutical industry, and Repligen Corporation (NASDAQ:RGEN), a
global life sciences company focused on bioprocessing technologies, have entered into a collaboration agreement to integrate
Repligen’s XCell™ ATF cell retention control technology into SSB’s BIOSTAT® STR large-scale single-use bioreactors to
create novel perfusion-enabled bioreactors. As a result of this collaboration, end users will stand to benefit from a single
control system for 50 L to 2,000 L bioreactors used in perfusion cell culture applications. This single interface is designed to
control cell growth, fluid management and cell retention in continuous and intensified bioprocessing and, ultimately, simplify the
development and cGMP manufacture of biological drugs.
Through the partnership, Sartorius Stedim Biotech and Repligen will further collaborate to equip SSB’s recently
launched ambr® 250ht perfusion single-use mini bioreactor system with Repligen’s KrosFlo® hollow fiber filter
technology. The bioreactor system will be sold by SSB as a complete single-use assembly. This optimal design conserves hollow fiber
filter technology across scales, enabling customers to fast track development and scale up their cell culture perfusion
processes.
“Sartorius Stedim Biotech has continuously expanded its integrated upstream portfolio over the past years with a
focus on robust and scalable, automated single-use solutions, optimized for high-cell-density applications. The collaboration with
Repligen will result in easy-to-implement, high-performance and perfusion-ready bioreactors ranging from process development to
commercial manufacturing scale,” commented Stefan Schlack, Head of Marketing at SSB.
Christine Gebski, Vice President of Product Management at Repligen, stated, “We are excited to partner with
Sartorius Stedim Biotech, a global innovator in bioreactor technology. The integration of our market-leading XCell™ ATF control
technology with SSB’s high-performance bioreactors offers a simplified perfusion-enabled bioreactor solution for end users to
develop cell culture processes more quickly and implement perfusion more efficiently.”
Image Files for Downloading:
Photo Link BIOSTAT STR bioreactor
For perfusion cell culture application Repligen’s XCell™ ATF cell retention control technology will be integrated into SSB’s
BIOSTAT® STR large-scale single-use bioreactors
Photo Link Repligen XCell™ ATF
Repligen’s XCell™ ATF cell retention device is shown to significantly increase bioreactor productivity; shown is the single-use
XCell™ ATF 10
Photo Link ambr 250ht perfusion bioreactor
SSB’s recently launched ambr® 250ht perfusion bioreactor system is equipped with Repligen’s KrosFlo®
hollow fiber filter technology
About Sartorius Stedim Biotech
Sartorius Stedim Biotech is a leading international supplier of products and services that enable the biopharmaceutical industry to
develop and manufacture drugs safely and efficiently. As a total solutions provider, Sartorius Stedim Biotech offers a portfolio
covering nearly all steps of biopharmaceutical manufacture. The company focuses on single-use technologies and value-added services
to meet the rapidly changing technology requirements of the industry it serves. Headquartered in Aubagne, France, Sartorius Stedim
Biotech is quoted on the Eurolist of Euronext Paris. With its own manufacturing and R&D sites in Europe, North America and Asia
and an international network of sales companies, Sartorius Stedim Biotech has a global reach. In 2017, the company employed approx.
5,100 people, and earned sales revenue of €1,081.0 million.
For further information, visit www.sartorius.com.
This press release contains statements about the future development of the Sartorius Stedim Biotech Group.
We cannot guarantee that the content of these statements will actually apply because these statements are based upon assumptions
and estimates that harbor certain risks and uncertainties.
About Repligen Corporation
Repligen Corporation (NASDAQ:RGEN) is a global bioprocessing company that develops and commercializes highly innovative products
that deliver cost and process efficiencies to biological drug manufacturers worldwide. The Company’s portfolio includes protein
products (Protein A affinity ligands, cell culture growth factors), chromatography products (OPUS® pre-packed columns,
chromatography resins, ELISA kits) and filtration products (including XCell™ ATF systems, TangenX™ Sius™ flat sheet TFF cassettes,
and Spectrum KrosFlo™ hollow fiber TFF cartridges and systems). The XCell™ ATF Systems, available in stainless steel and single-use
configurations, are used upstream to continuously eliminate waste from a bioreactor, to concentrate cells and increase product
yield. Repligen’s corporate headquarters are in Waltham, MA (USA), with additional administrative and manufacturing operations in
Shrewsbury, MA, Rancho Dominguez, CA, Lund, Sweden and Ravensburg, Germany.
For further information, visit www.repligen.com.
The following constitutes a “Safe Harbor” statement under the Private Securities Litigation Reform Act of
1995: This press release contains forward-looking statements, which are made pursuant to the safe harbor provisions of Section 27A
of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Investors are
cautioned that statements in this press release which are not strictly historical statements, including, without limitation,
express or implied statements regarding Repligen’s partnership with Sartorius Stedim Biotech, the impact of a single control system
on Repligen’s end users, and the future financial performance of Repligen constitute forward-looking statements identified by words
like “believe,” “expect,” “may,” “will,” “should,” “seek,” “anticipate,” or “could” and similar expressions. Such forward-looking
statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those
anticipated, including, without limitation, risks associated with: our ability to successfully grow our bioprocessing business,
including as a result of acquisition, commercialization or partnership opportunities; our ability to successfully integrate any
acquisitions, our ability to develop and commercialize products and the market acceptance of our products; reduced demand for our
products that adversely impacts our future revenues, cash flows, results of operations and financial condition; our ability to
compete with larger, better financed bioprocessing, pharmaceutical and biotechnology companies; our compliance with all Food and
Drug Administration and EMEA regulations; our volatile stock price; and other risks detailed in Repligen’s most recent Annual
Report on Form 10-K on file with the Securities and Exchange Commission and the other reports that Repligen periodically files with
the Securities and Exchange Commission. Actual results may differ materially from those Repligen contemplated by these
forward-looking statements. These forward looking statements reflect management’s current views and Repligen does not undertake to
update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the
date hereof except as required by law.
Contacts:
For Sartorius Stedim Biotech:
Dominic
Grone
Corporate
Communications
Sartorius Corporate Administration GmbH
Phone: +49 (0)551.308.3324
Email: dominic.grone@sartorius.com
For Repligen:
Sondra Newman
Senior Director Investor Relations
Phone: 781-419-1881
Email: snewman@repligen.com
Photos accompanying this announcement are available at:
http://www.globenewswire.com/NewsRoom/AttachmentNg/d7943d34-ce7e-4c7d-8369-502ef1a62e66
http://www.globenewswire.com/NewsRoom/AttachmentNg/3c4625e0-3a0b-42b4-81d4-4554de5f393d
http://www.globenewswire.com/NewsRoom/AttachmentNg/ceeecd36-a6fd-44b3-ba8d-969ae51ee32c
